The drugs setegis 2 mg, camiren 2 mg, were used in the investigation designed to study economic and clinical effectiveness of employment of <$E alpha>-blockers for treating chronic prostatitis, with the expediency of the above therapeutic modality having been corraborated by the findings secured. Objective control of the treatments administered necessitates studying the time-related changes in indices for the amount of the residual urine and volume of the prostate. Economic expediency has been shown of use of camiren 2 mg, an <$E alpha>-blocker, of the KRKA firm, which fact was validated by a lower cost of the drug at the retail market of Ukraine compared to setegis 2 mg.

  Якщо, ви не знайшли інформацію про автора(ів) публікації, маєте бажання виправити або відобразити більш докладну інформацію про науковців України запрошуємо заповнити "Анкету науковця"